ISRG vs PFE

Intuitive Surgical (ISRG) continues to demonstrate strong operational performance, evidenced by its Q4 2025 revenue growth of 18.8% YoY and robust EPS beat. It maintains its undisputed leadership in robotic-assisted surgery, supported by a growing installed base of 11,423 da Vinci systems and impressive Ion system adoption. The company's formidable moat, built on IP, high switching costs, and exte...

Pfizer Inc. remains a mature, large-cap pharmaceutical company with no material changes since the last analysis that would indicate a path to 10x growth. The company faces ongoing headwinds from declining COVID product sales and patent cliffs. While a settlement extended Vyndamax exclusivity, this is insufficient to offset broader challenges. Upcoming Q1 2026 earnings are projected to show a ~20% ...